The Eden Prairie, Minn.-based company said it plans to offer 2.2 million shares of its common stock at $2.12 per share. The offering includes a 45-day underwriter’s option for an additional 332,239 shares at the public offering price.
Ladenburg Thalmann & Co are acting as sole book-running manager for the offering, with Dawson James Securities acting as co-manager, according to a press release. The offering is expected to close July 3.
CHF Solutions said it plans to use net proceeds for general corporate purposes, including the expansion of its field sales force and commercial organization.
In May, CHF Solutions saw shares fall after the heart-focused medical device maker missed expectations on Wall Street with its first quarter earnings results.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.